Limits...
Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.

Moré MI, Swidsinski A - Clin Exp Gastroenterol (2015)

Bottom Line: Its action is based on multiple mechanisms, including immunological effects, pathogen-binding and antitoxinic effects, as well as effects on digestive enzymes.The previously observed preventive action of S. boulardii, eg, during antibiotic therapy or regarding traveler's diarrhea, can be explained by several mechanisms, including a stabilizing effect on the healthy microbiota as well as possibly on the mucus layer.Several different dysbiotic situations could profit from the effects of S. boulardii CNCM I-745.

View Article: PubMed Central - PubMed

Affiliation: analyze & realize GmbH, Berlin, Germany.

ABSTRACT
The probiotic medicinal yeast Saccharomyces cerevisiae HANSEN CBS 5926 (Saccharomyces boulardii CNCM I-745) is used for the prevention and treatment of diarrhea. Its action is based on multiple mechanisms, including immunological effects, pathogen-binding and antitoxinic effects, as well as effects on digestive enzymes. Correlated with these effects, but also due to its inherent properties, S. boulardii is able to create a favorable growth environment for the beneficial intestinal microbiota, while constituting extra protection to the host mucus layer and mucosa. This review focuses on the positive influence of S. boulardii on the composition of the intestinal microbiota. In a dysbiosis, as during diarrhea, the main microbial population (especially Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, and Prevotellaceae) is known to collapse by at least one order of magnitude. This gap generally leads to transient increases in pioneer-type bacteria (Enterobacteriaceae, Bifidobacteriaceae, and Clostridiaceae). Several human studies as well as animal models demonstrate that treatment with S. boulardii in dysbiosis leads to the faster reestablishment of a healthy microbiome. The most relevant effects of S. boulardii on the fecal composition include an increase of short chain fatty acid-producing bacteria (along with a rise in short chain fatty acids), especially of Lachnospiraceae and Ruminococcaceae, as well as an increase in Bacteroidaceae and Prevotellaceae. At the same time, there is a suppression of pioneer bacteria. The previously observed preventive action of S. boulardii, eg, during antibiotic therapy or regarding traveler's diarrhea, can be explained by several mechanisms, including a stabilizing effect on the healthy microbiota as well as possibly on the mucus layer. Several different dysbiotic situations could profit from the effects of S. boulardii CNCM I-745. Its additional potential lies in a general stabilization of the gut flora for at-risk populations. More studies are needed to explore the full potential of this versatile probiotic yeast.

No MeSH data available.


Related in: MedlinePlus

Generalized scheme of the effects of antibiotic dysbiosis on habitual/essential bacteria and other substantial bacteria.Notes: Upon a 2-week antibiotic treatment (red area), the main microbial population suffers an abrupt decrease (blue line). Saccharomyces boulardii administered during antibiotic treatment (red area; red line) can reduce this decline by protecting the microbiota. If instead S. boulardii is administered following antibiotic treatment (green area; green line), S. boulardii can support a faster regeneration of the microbial population. Accordingly, the optimum would be a combination of both, a treatment with S. boulardii during and following antibiotic treatment. This is represented by the hypothetical black dotted line, which was derived from the other lines. The worst-case scenario is no S. boulardii treatment (blue line). Pioneer bacteria and accidental bacteria are excluded.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4542552&req=5

f2-ceg-8-237: Generalized scheme of the effects of antibiotic dysbiosis on habitual/essential bacteria and other substantial bacteria.Notes: Upon a 2-week antibiotic treatment (red area), the main microbial population suffers an abrupt decrease (blue line). Saccharomyces boulardii administered during antibiotic treatment (red area; red line) can reduce this decline by protecting the microbiota. If instead S. boulardii is administered following antibiotic treatment (green area; green line), S. boulardii can support a faster regeneration of the microbial population. Accordingly, the optimum would be a combination of both, a treatment with S. boulardii during and following antibiotic treatment. This is represented by the hypothetical black dotted line, which was derived from the other lines. The worst-case scenario is no S. boulardii treatment (blue line). Pioneer bacteria and accidental bacteria are excluded.

Mentions: A generalized scheme of the effects of S. boulardii is depicted in Figure 2. From the curves we conclude that the optimal treatment would be to administer S. boulardii simultaneously to the antibiotic treatment, plus subsequently for at least 2 weeks.


Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a review.

Moré MI, Swidsinski A - Clin Exp Gastroenterol (2015)

Generalized scheme of the effects of antibiotic dysbiosis on habitual/essential bacteria and other substantial bacteria.Notes: Upon a 2-week antibiotic treatment (red area), the main microbial population suffers an abrupt decrease (blue line). Saccharomyces boulardii administered during antibiotic treatment (red area; red line) can reduce this decline by protecting the microbiota. If instead S. boulardii is administered following antibiotic treatment (green area; green line), S. boulardii can support a faster regeneration of the microbial population. Accordingly, the optimum would be a combination of both, a treatment with S. boulardii during and following antibiotic treatment. This is represented by the hypothetical black dotted line, which was derived from the other lines. The worst-case scenario is no S. boulardii treatment (blue line). Pioneer bacteria and accidental bacteria are excluded.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4542552&req=5

f2-ceg-8-237: Generalized scheme of the effects of antibiotic dysbiosis on habitual/essential bacteria and other substantial bacteria.Notes: Upon a 2-week antibiotic treatment (red area), the main microbial population suffers an abrupt decrease (blue line). Saccharomyces boulardii administered during antibiotic treatment (red area; red line) can reduce this decline by protecting the microbiota. If instead S. boulardii is administered following antibiotic treatment (green area; green line), S. boulardii can support a faster regeneration of the microbial population. Accordingly, the optimum would be a combination of both, a treatment with S. boulardii during and following antibiotic treatment. This is represented by the hypothetical black dotted line, which was derived from the other lines. The worst-case scenario is no S. boulardii treatment (blue line). Pioneer bacteria and accidental bacteria are excluded.
Mentions: A generalized scheme of the effects of S. boulardii is depicted in Figure 2. From the curves we conclude that the optimal treatment would be to administer S. boulardii simultaneously to the antibiotic treatment, plus subsequently for at least 2 weeks.

Bottom Line: Its action is based on multiple mechanisms, including immunological effects, pathogen-binding and antitoxinic effects, as well as effects on digestive enzymes.The previously observed preventive action of S. boulardii, eg, during antibiotic therapy or regarding traveler's diarrhea, can be explained by several mechanisms, including a stabilizing effect on the healthy microbiota as well as possibly on the mucus layer.Several different dysbiotic situations could profit from the effects of S. boulardii CNCM I-745.

View Article: PubMed Central - PubMed

Affiliation: analyze & realize GmbH, Berlin, Germany.

ABSTRACT
The probiotic medicinal yeast Saccharomyces cerevisiae HANSEN CBS 5926 (Saccharomyces boulardii CNCM I-745) is used for the prevention and treatment of diarrhea. Its action is based on multiple mechanisms, including immunological effects, pathogen-binding and antitoxinic effects, as well as effects on digestive enzymes. Correlated with these effects, but also due to its inherent properties, S. boulardii is able to create a favorable growth environment for the beneficial intestinal microbiota, while constituting extra protection to the host mucus layer and mucosa. This review focuses on the positive influence of S. boulardii on the composition of the intestinal microbiota. In a dysbiosis, as during diarrhea, the main microbial population (especially Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, and Prevotellaceae) is known to collapse by at least one order of magnitude. This gap generally leads to transient increases in pioneer-type bacteria (Enterobacteriaceae, Bifidobacteriaceae, and Clostridiaceae). Several human studies as well as animal models demonstrate that treatment with S. boulardii in dysbiosis leads to the faster reestablishment of a healthy microbiome. The most relevant effects of S. boulardii on the fecal composition include an increase of short chain fatty acid-producing bacteria (along with a rise in short chain fatty acids), especially of Lachnospiraceae and Ruminococcaceae, as well as an increase in Bacteroidaceae and Prevotellaceae. At the same time, there is a suppression of pioneer bacteria. The previously observed preventive action of S. boulardii, eg, during antibiotic therapy or regarding traveler's diarrhea, can be explained by several mechanisms, including a stabilizing effect on the healthy microbiota as well as possibly on the mucus layer. Several different dysbiotic situations could profit from the effects of S. boulardii CNCM I-745. Its additional potential lies in a general stabilization of the gut flora for at-risk populations. More studies are needed to explore the full potential of this versatile probiotic yeast.

No MeSH data available.


Related in: MedlinePlus